NP
BMRN icon

NS Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

NS Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-44,445
Closed -$4.04M – 103
2017
Q2 		$4.04M Buy
44,445
+2,530
+6% +$230K 0.53% 69
2017
Q1 		$3.68M Buy
41,915
+61
+0.1% +$5.43K 0.53% 71
2016
Q4 		$3.47M Buy
41,854
+10,188
+32% +$876K 0.54% 78
2016
Q3 		$2.93M Sell
31,666
-35
-0.1% -$3.3K 0.48% 80
2016
Q2 		$2.47M Buy
31,701
+25,241
+391% +$2.15M 0.42% 81
2016
Q1 		$533K Buy
+6,460
New +$526K 0.1% 102

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NS Partners's BMRN Position: Q3 2017 in Review

NS Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2017, closing a stake of 44,445 shares — an estimated $4.04M sold.

NS Partners first reported a position in BMRN in Q1 2016 and held it in 6 quarters. The position peaked at $4.04M in Q2 2017. 411 funds tracked by Wall St. Rank hold BMRN as of Q3 2017.

  • NS Partners reported no remaining BioMarin Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • NS Partners sold 44,445 BioMarin Pharmaceuticals shares in Q3 2017, an estimated $4.04M.
  • NS Partners first reported a position in BioMarin Pharmaceuticals in Q1 2016 and held it in 6 quarters.
  • NS Partners's BioMarin Pharmaceuticals position peaked at $4.04M in Q2 2017.
  • 411 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2017.

Based on NS Partners's 13F filing for Q3 2017, filed 14 Nov 2017.